Should I buy or sell Gritstone bio stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gritstone bio in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GRTS shares. View GRTS analyst ratings or view top-rated stocks .

What is Gritstone bio's stock price target for 2024?

3 equities research analysts have issued 12-month price objectives for Gritstone bio's shares. Their GRTS share price targets range from $5.00 to $7.00. On average, they predict the company's share price to reach $6.33 in the next year. This suggests a possible upside of 751.6% from the stock's current price. View analysts price targets for GRTS or view top-rated stocks among Wall Street analysts .

How have GRTS shares performed in 2024?

Gritstone bio's stock was trading at $2.04 at the beginning of 2024. Since then, GRTS stock has decreased by 63.5% and is now trading at $0.7437. View the best growth stocks for 2024 here .

When is Gritstone bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our GRTS earnings forecast .

How were Gritstone bio's earnings last quarter?

Gritstone bio, Inc. (NASDAQ:GRTS) released its earnings results on Tuesday, March, 5th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.10. The business had revenue of $10.38 million for the quarter, compared to the consensus estimate of $4.80 million. Gritstone bio had a negative trailing twelve-month return on equity of 147.22% and a negative net margin of 847.24%.

What ETF holds Gritstone bio's stock?

Morningstar US Small Growth holds 23,628 shares of GRTS stock, representing 2.17% of its portfolio.

What is Andrew Allen's approval rating as Gritstone bio's CEO?

1 employees have rated Gritstone bio Chief Executive Officer Andrew Allen on Glassdoor.com . Andrew Allen has an approval rating of 100% among the company's employees. This puts Andrew Allen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Gritstone bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gritstone bio investors own include ADMA Biologics (ADMA) , Bionano Genomics (BNGO) , Matinas BioPharma (MTNB) , Novan (NOVN) , Sorrento Therapeutics (SRNE) , Zosano Pharma (ZSAN) , Enerplus (ERF) , Oncolytics Biotech (ONCY) , SCYNEXIS (SCYX) and CBL & Associates Properties (CBL) .

When did Gritstone bio IPO?

Gritstone bio (GRTS) raised $85 million in an IPO on Friday, September 28th 2018. The company issued 6,100,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays served as the underwriters for the IPO and BTIG was co-manager.

How do I buy shares of Gritstone bio?

Shares of GRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:GRTS

Gritstone bio (GRTS) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free GRTS Stock Alerts

$0.74

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.72
▼
$0.77
50-Day Range: $0.74
▼
$2.84
52-Week Range: $0.67
▼
$3.33

Volume: 2.11 million shs
Average Volume: 2.86 million shs
Market Capitalization: $72.93 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.33

Get Gritstone bio alerts:

Gritstone bio MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 751.6% Upside
$6.33 Price Target
Short Interest: Bearish
9.40% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.81
Based on 11 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.91) to ($0.88) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.09 out of 5 stars

Medical Sector

606th out of 918 stocks

Biological Products, Except Diagnostic Industry

96th out of 147 stocks

3.5

Analyst's Opinion

Consensus Rating
Gritstone bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Gritstone bio has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
9.40% of the float of Gritstone bio has been sold short.
Short Interest Ratio / Days to Cover
Gritstone bio has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Gritstone bio has recently increased by 3.40%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Gritstone bio does not currently pay a dividend.
Dividend Growth
Gritstone bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GRTS.

3.8

News and Social Media Coverage

News Sentiment
Gritstone bio has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Gritstone bio this week, compared to 2 articles on an average week.
Search Interest
17 people have searched for GRTS on MarketBeat in the last 30 days. This is an increase of 70% compared to the previous 30 days.
MarketBeat Follows
8 people have added Gritstone bio to their MarketBeat watchlist in the last 30 days. This is an increase of 14% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Gritstone bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.61% of the stock of Gritstone bio is held by insiders.
Percentage Held by Institutions
48.46% of the stock of Gritstone bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Gritstone bio are expected to grow in the coming year, from ($0.91) to ($0.88) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Gritstone bio is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Gritstone bio is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Gritstone bio has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Gritstone bio Stock (NASDAQ:GRTS)

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

GRTS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GRTS Stock News Headlines

April 18, 2024 | americanbankingnews.com

Equities Analysts Issue Forecasts for Gritstone bio, Inc.'s Q1 2024 Earnings (NASDAQ:GRTS)

April 18, 2024 | americanbankingnews.com

Research Analysts Offer Predictions for Gritstone bio, Inc.'s Q2 2024 Earnings (NASDAQ:GRTS)

April 19, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

April 15, 2024 | finance.yahoo.com

Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)

April 15, 2024 | globenewswire.com

Nature Medicine Publishes Interim Results from Gritstone bio's Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)

April 12, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS

April 10, 2024 | stockhouse.com

Gritstone bio Presents Improvements to EDGE(TM) Platform at AACR 2024

April 8, 2024 | markets.businessinsider.com

Buy Rating Affirmed: Gritstone Oncology’s Promising Growth and Technological Advancements

April 19, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

April 8, 2024 | finance.yahoo.com

Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024

April 4, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS

April 3, 2024 | benzinga.com

Gritstone Bio Stock (NASDAQ:GRTS), Quotes and News Summary

April 2, 2024 | markets.businessinsider.com

Nasdaq Down Over 1%; VivoPower International Shares Spike Higher

April 2, 2024 | msn.com

What's Going On With Small Cap Cancer Vaccine Focused Gritstone Bio Stock On Tuesday?

April 2, 2024 | investorplace.com

Why Are Health Insurance Stocks HUM, UNH, CI Down Today?

April 2, 2024 | marketwatch.com

Gritstone Bio Shares Drop 33% After Public Offering Prices

April 2, 2024 | investorplace.com

Why Is Gritstone Bio (GRTS) Stock Down 44% Today?

April 1, 2024 | globenewswire.com

Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering

April 1, 2024 | msn.com

Gritstone stock plunges 35% on mixed Phase 2 data, public offering

April 1, 2024 | globenewswire.com

Gritstone bio Announces Proposed Public Offering

April 1, 2024 | globenewswire.com

Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

March 28, 2024 | seekingalpha.com

GRTS Gritstone bio, Inc.

March 19, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS

March 18, 2024 | msn.com

Do Options Traders Know Something About Gritstone bio (GRTS) Stock We Don't?

March 8, 2024 | finance.yahoo.com

Gritstone bio, Inc. (NASDAQ:GRTS) Just Reported And Analysts Have Been Cutting Their Estimates

March 7, 2024 | finance.yahoo.com

Gritstone Bio Inc (GRTS) Reports Fiscal Year 2023 Financial Results and Corporate Updates

March 7, 2024 | finance.yahoo.com

Gritstone bio Full Year 2023 Earnings: Beats Expectations

See More Headlines

Receive GRTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gritstone bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/05/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:GRTS
CUSIP: N/A
CIK: 1656634
Web: www.gritstoneoncology.com
Phone: (510) 871-6100
Fax: N/A
Employees: 231
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.33
High Stock Price Target: $7.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +751.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-138,490,000.00
Net Margins: -847.24%
Pretax Margin: -847.34%
Return on Equity: -147.22%
Return on Assets: -69.46%

Debt

Debt-to-Equity Ratio: 0.77
Current Ratio: 3.20
Quick Ratio: 3.20

Sales & Book Value

Annual Sales: $16.34 million
Price / Sales: 4.46
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.54 per share
Price / Book: 1.38

Miscellaneous

Outstanding Shares: 98,070,000
Free Float: 93,545,000
Market Cap: $72.93 million
Optionable: Optionable
Beta: 0.38

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Dr. Andrew R. Allen BCh (Age 58)
BM, M.D., MA, MRCP, Ph.D., Co-Founder, President, CEO & Director
Comp: $983.44k
Mr. Erin E. Jones M.S. (Age 52)
Executive VP & COO
Comp: $658.01k
Dr. Karin Jooss Ph.D. (Age 58)
Executive VP and Head of Research & Development
Comp: $706.07k
Ms. Vassiliki Economides (Age 43)
Executive VP & CFO
Mr. James Cho
Chief Accounting Officer
George MacDougall
Director of Investor Relations & Corporate Communications
Ms. Stacy Proctor
Executive VP & Chief People Officer
Dr. Matthew J. Hawryluk M.B.A. (Age 45)
Ph.D., Executive VP & Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GRTS Stock Analysis - Frequently Asked Questions

Should I buy or sell Gritstone bio stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gritstone bio in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GRTS shares.
View GRTS analyst ratings or view top-rated stocks.
What is Gritstone bio's stock price target for 2024?: 3 equities research analysts have issued 12-month price objectives for Gritstone bio's shares. Their GRTS share price targets range from $5.00 to $7.00. On average, they predict the company's share price to reach $6.33 in the next year. This suggests a possible upside of 751.6% from the stock's current price.
View analysts price targets for GRTS or view top-rated stocks among Wall Street analysts.
How have GRTS shares performed in 2024?: Gritstone bio's stock was trading at $2.04 at the beginning of 2024. Since then, GRTS stock has decreased by 63.5% and is now trading at $0.7437.
View the best growth stocks for 2024 here.
When is Gritstone bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our GRTS earnings forecast.
How were Gritstone bio's earnings last quarter?: Gritstone bio, Inc. (NASDAQ:GRTS) released its earnings results on Tuesday, March, 5th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.10. The business had revenue of $10.38 million for the quarter, compared to the consensus estimate of $4.80 million. Gritstone bio had a negative trailing twelve-month return on equity of 147.22% and a negative net margin of 847.24%.
What ETF holds Gritstone bio's stock?: Morningstar US Small Growth holds 23,628 shares of GRTS stock, representing 2.17% of its portfolio.

What is Andrew Allen's approval rating as Gritstone bio's CEO?: 1 employees have rated Gritstone bio Chief Executive Officer Andrew Allen on Glassdoor.com. Andrew Allen has an approval rating of 100% among the company's employees. This puts Andrew Allen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Gritstone bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Gritstone bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Novan (NOVN), Sorrento Therapeutics (SRNE), Zosano Pharma (ZSAN), Enerplus (ERF), Oncolytics Biotech (ONCY), SCYNEXIS (SCYX) and CBL & Associates Properties (CBL).
When did Gritstone bio IPO?: Gritstone bio (GRTS) raised $85 million in an IPO on Friday, September 28th 2018. The company issued 6,100,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays served as the underwriters for the IPO and BTIG was co-manager.
How do I buy shares of Gritstone bio?: Shares of GRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GRTS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Gritstone bio (GRTS) Stock Price, News & Analysis

Gritstone bio MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Gritstone bio Stock (NASDAQ:GRTS)

GRTS Stock Price History

GRTS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

GRTS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™